BI/Lilly Bring Third Entrant To SGLT2 Market With Jardiance Approval

The type 2 diabetes space gets more crowded as FDA hands out another approval for an SGLT-2 inhibitor after an earlier rejection in March due to manufacturing issues.

More from United States

More from North America